Myriad Genetics to Acquire Crescendo Bioscience

Myriad Genetics to Acquire Crescendo Bioscience® Diversifies Myriad’s Product Portfolio into High Growth Autoimmune Market SALT LAKE CITY, Utah, February 4, 2014 – Myriad Genetics, Inc. (NASDAQ: MYGN) announced today that it has entered into a definitive agreement to acquire Crescendo Bioscience, Inc., a global leader in autoimmune diagnostics, for $270 million in cash which […]

Read More

Crescendo Bioscience, Inc. Ranked Number 27th Fastest Growing Company in North America on Deloitte’s 2013 Technology Fast 500

Crescendo Bioscience, Inc. Ranked Number 27th Fastest Growing Company in North America on Deloitte’s 2013 Technology Fast 500™ Molecular Diagnostic Company Attributes 8,753.0 Percent Revenue Growth to Unmet Need in Rheumatology Community South San Francisco–November 13, 2013– Crescendo Bioscience, a molecular diagnostics company dedicated to developing quantitative blood tests and disease information services for rheumatoid […]

Read More

Crescendo Bioscience™, Inc. announces the U.S. launch of the first multi-biomarker blood test for rheumatoid arthritis disease activity

Crescendo Bioscience™, Inc. announces the U.S. launch of the first multi-biomarker blood test for rheumatoid arthritis disease activity Vectra™ DA Launched at the ACR /ARHP Annual Scientific Meeting South San Francisco, Calif. – November 8, 2010 – Crescendo Bioscience announced today the commercial launch of Vectra DA, its first-in-class multi-biomarker blood test designed to aid […]

Read More

Crescendo Bioscience Increases Presence at the American College of Rheumatology/Association of Rheumatology Health Professionals Annual Meeting

Crescendo Bioscience Increases Presence at the American College of Rheumatology/Association of Rheumatology Health Professionals Annual Meeting Oral Presentation from Brigham and Women’s Hospital and Harvard Medical School Study (BRASS) Will Demonstrate Vectra DA’s Ability to Measure RA Disease Activity Independent of Fibromyalgia and Despite Low CRP Level SOUTH SAN FRANCISCO, Calif., Oct. 28, 2013 — […]

Read More